Idhifa

Chemical Nameenasidenib
Dosage FormTablet (oral; 50 mg, 100 mg)
Drug ClassInhibitors
SystemBlood
CompanyCelgene Corporation
Approval Year2017

Indication

  • For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Idhifa (enasidenib) Prescribing Information 2019Celgene Corporation, Summit, NJ
Document TitleYearSource
Enasidenib (Idhifa) for acute myeloid leukemia. 2019CADTH